MDxHealth SA (NASDAQ:MDXH) Given Consensus Recommendation of “Moderate Buy” by Brokerages

MDxHealth SA (NASDAQ:MDXH) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $7.75.

Several equities research analysts have recently commented on the company. TD Cowen upped their target price on shares of MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Lake Street Capital raised their price objective on shares of MDxHealth from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. BTIG Research reiterated a “buy” rating and set a $7.00 target price on shares of MDxHealth in a research report on Tuesday, December 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research note on Monday, December 29th.

MDxHealth Stock Performance

Shares of NASDAQ:MDXH opened at $3.53 on Friday. The business has a fifty day moving average of $3.53 and a 200-day moving average of $3.75. The firm has a market cap of $174.74 million, a PE ratio of -5.52 and a beta of 1.64. MDxHealth has a twelve month low of $1.35 and a twelve month high of $5.33.

Institutional Trading of MDxHealth

Several hedge funds have recently added to or reduced their stakes in the business. Kennedy Capital Management LLC bought a new position in shares of MDxHealth during the 3rd quarter valued at about $1,826,000. Marshall Wace LLP bought a new position in MDxHealth in the fourth quarter valued at approximately $609,000. Mink Brook Asset Management LLC bought a new position in MDxHealth in the third quarter valued at approximately $743,000. Panoramic Capital LLC acquired a new position in shares of MDxHealth in the third quarter valued at approximately $721,000. Finally, FreeGulliver LLC increased its position in shares of MDxHealth by 104.7% during the third quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock worth $1,176,000 after acquiring an additional 129,348 shares in the last quarter.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.